SNDL is trading 5.6% up at $1.31 today after announcing the completion of its acquisition of certain assets from Parallel, a U.S. cannabis operator. This strategic transaction is a significant company-specific catalyst.
- The acquisition includes 56 retail locations and three cultivation and manufacturing facilities across Florida, Texas, and Massachusetts, and extinguished approximately $842 million of Parallel's debt obligations.
- The deal provides SNDL with indirect majority economic exposure to U.S. medical cannabis operations, positioning it for potential direct consolidation into Nasdaq-listed U.S. medical cannabis operations.
- The stock's upward movement also occurs ahead of its Q2 2026 earnings report, expected on July 28, with investors anticipating progress towards profitability.